Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter H Goff

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Ebiomedicine|November 3, 2019
Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanomaGayathri Vijayakumar, Peter Palese, Peter H Goff
Journal of Virology|October 25, 2013
Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domainDirk Eggink, Peter H Goff, Peter Palese
Journal of Virology|July 13, 2012
A majority of infectious Newcastle disease virus particles contain a single genome, while a minority contain multiple genomesPeter H Goff, Qinshan Gao, Peter Palese
JAMA Dermatology|March 20, 2024
Considerations Regarding Mohs Surgery for Early-Stage Merkel Cell CarcinomaSuraj S Venna, Peter H Goff, Isaac Brownell
Seminars in Radiation Oncology|February 21, 2021
Radiation and Modulation of the Tumor Immune Microenvironment in Non-Small Cell Lung CancerPeter H Goff, Jing Zeng, Ramesh Rengan, et al.
The Journal of Experimental Medicine|June 11, 2008
Sgamma3 switch sequences function in place of endogenous Sgamma1 to mediate antibody class switchingAli A Zarrin, Peter H Goff, Kate Senger, et al.
Journal of Virology|October 7, 2011
The cargo-binding domain of transportin 3 is required for lentivirus nuclear importEric C Logue, Kayleigh T Taylor, Peter H Goff, et al.
Advances in Radiation Oncology|July 1, 2021
In Regard to BarkerPeter H Goff, Stephanie K Schaub, Maclean M Cook, et al.
Journal for Immunotherapy of Cancer|July 25, 2024
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapyTomoko Akaike, Austin J Jabbour, Peter H Goff, et al.
Cancers|July 24, 2021
Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?Peter H Goff, Rashmi Bhakuni, Thomas Pulliam, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Ebiomedicine|November 3, 2019
Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanomaGayathri Vijayakumar, Peter Palese, Peter H Goff
Journal of Virology|October 25, 2013
Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domainDirk Eggink, Peter H Goff, Peter Palese
Journal of Virology|July 13, 2012
A majority of infectious Newcastle disease virus particles contain a single genome, while a minority contain multiple genomesPeter H Goff, Qinshan Gao, Peter Palese
JAMA Dermatology|March 20, 2024
Considerations Regarding Mohs Surgery for Early-Stage Merkel Cell CarcinomaSuraj S Venna, Peter H Goff, Isaac Brownell
Seminars in Radiation Oncology|February 21, 2021
Radiation and Modulation of the Tumor Immune Microenvironment in Non-Small Cell Lung CancerPeter H Goff, Jing Zeng, Ramesh Rengan, et al.
The Journal of Experimental Medicine|June 11, 2008
Sgamma3 switch sequences function in place of endogenous Sgamma1 to mediate antibody class switchingAli A Zarrin, Peter H Goff, Kate Senger, et al.
Journal of Virology|October 7, 2011
The cargo-binding domain of transportin 3 is required for lentivirus nuclear importEric C Logue, Kayleigh T Taylor, Peter H Goff, et al.
Advances in Radiation Oncology|July 1, 2021
In Regard to BarkerPeter H Goff, Stephanie K Schaub, Maclean M Cook, et al.
Journal for Immunotherapy of Cancer|July 25, 2024
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapyTomoko Akaike, Austin J Jabbour, Peter H Goff, et al.
Cancers|July 24, 2021
Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?Peter H Goff, Rashmi Bhakuni, Thomas Pulliam, et al.
Pageof 3